Skip to main content

Table 3 Summary of studies in complicated urinary tract infection (cUTI)

From: Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

   CCR-TOC/ITTa     
Index Reference Agent A Agent B Description Quality Comparative outcome (A vs B) Year
M [38] Doripenem 95.1 % (272/286) Levofloxacin 90.2 % (240/266) P3, R H Noninferior 2009
N [39] Doripenem 94.1 % (511/543) Levofloxacin 90.2 % (240/266) See comments H Noninferior 2010
O [40] Ceftolozane-tazobactam 95.9 % (327/341) ME Levofloxacin 93.2 % (329/353) ME R, DB, P3 H Noninferior  
P [41] Ceftazidime-avibactam 85.7 % (24/28) Imipenem-cilastatin 80.6 % (29/36) P2, DB, R M - 2012
  1. CCR-TOC/ITT clinical cure rate at the test-of-cure endpoint intent-to-treat, DB double-blind, ME microbiological eradication, OL open-label, P2 phase 2, P3 phase 3, R randomized.
  2. aUnless otherwise noted.